ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO1895

Large Abdominal Mass: An Unusual Presentation of Multiple Myeloma

Session Information

Category: Onco-Nephrology

  • 1500 Onco-Nephrology

Authors

  • Khan, Naseer, Medical City Dallas Hospital, Dallas, Texas, United States
  • Nadella, Rama, Medical City Dallas Hospital, Dallas, Texas, United States
  • Proctor, Gregory W., Medical City Dallas Hospital, Dallas, Texas, United States
  • Cespedes, Paul L., Medical City Dallas Hospital, Dallas, Texas, United States
  • Agha, Irfan, Medical City Dallas Hospital, Dallas, Texas, United States

Group or Team Name

  • Medical City Dallas Hospital, Dallas , TX
Introduction

Extramedullary Soft Tissue Mass (ESTM) is an infrequent presentation of Multiple Myeloma.
We present a unique case of Multiple Myeloma with very large bulky tumor masses.

Case Description

A 69 year old AA female presented with severe abdominal distention.
CT Scan showed a 17 x 10 x 10 cm mass originating in the retroperitoneal region, a 12.5 cm mass in the pelvis and a 4.3 x 2.7 cm mass in the liver as shown in the image.
Further testing showed anemia and renal failure.
Biopsy of the mass revealed multiple myeloma, driving a monoclonal IgG lambda clone. FISH panel was positive for 17P/TP53 deletion which is very unfavorable.
Patient was treated initially with dexamethasone/cyclophosphamide/Velcade and later with Daratumumab/Carfilzomib/dexamethasone without any response and remained on dialysis ultimately succumbing within 6 weeks of diagnosis.

Discussion

Initial Extramedullary Soft Tissue Mass (ESTM) manifestations in Multiple Myeloma occur in about 3% of the cases.

In a large majority (93.5%) these lesions are solitary.
Our patient had large, multiple masses with high tumor burden and unfavorable cytogenetic signature.
She did not respond to therapy despite utilization of aggressive regimens.

This is a very unique presentation of myeloma and with the unfavorable characteristics, had a dismal prognosis despite aggressive therapy.

CT Abd showing ESTM